Cost-benefit analysis of targeted hearing directed early testing for congenital cytomegalovirus infection

International Journal of Pediatric Otorhinolaryngology

Volumn 79, Issue 12, 2015, Pages 2090-2093

  Bergevin, Anna ^a   Zick, Cathleen D ^a   McVicar, Stephanie Browning ^b   Park, Albert H ^c  

^a UNIVERSITY OF UTAH   (United States)

^b UTAH DEPARTMENT OF HEALTH   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Cost benefit analysis; Cytomegalovirus; Sensorineural hearing loss

Indexed keywords

ANTIVIRAL THERAPY; ARTICLE; AUDITORY SCREENING; CHILD HEALTH CARE; COST BENEFIT ANALYSIS; COST CONTROL; CYTOMEGALOVIRUS INFECTION; EARLY DIAGNOSIS; GOVERNMENT; HEARING IMPAIRMENT; HUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; UNITED STATES; CYTOMEGALOVIRUS INFECTIONS; ECONOMICS; HEARING LOSS; LEGISLATION AND JURISPRUDENCE; NEWBORN; NEWBORN SCREENING; UTAH; VIROLOGY;

ANTIVIRUS AGENT;

ANTIVIRAL AGENTS; CHILD HEALTH SERVICES; COST-BENEFIT ANALYSIS; CYTOMEGALOVIRUS INFECTIONS; HEARING LOSS; HUMANS; INFANT, NEWBORN; NEONATAL SCREENING; UTAH;

EID: 84955196551     PISSN: 01655876     EISSN: 18728464     Source Type: Journal    
DOI: 10.1016/j.ijporl.2015.09.019     Document Type: Article

References (15)

1. Engman M.L., Malm G., Engstrom L., Petersson K., Karltorp E., Tear Fahnehjelm K., et al. Scand. J. Infect. Dis. 2008, 40:935-942.
2. Morton C.C., Nance W.E. N. Engl. J. Med. 2006, 354:2151-2164.
3. Grosse S.D., Ross D.S., Dollard S.C. J. Clin. Virol. 2008, 41:57-62.
4. Park A.H., Duval M., McVicar S., Bale J.F., Hohler N., Carey J.C. Laryngoscope 2014, 124(11):2624-2629.
5. American Academy of Pediatrics, Joint Committee on Infant Hearing Pediatrics 2007, 120:898-921.
6. Honeycutt A., Grosse S.D., Dunlap L. Economic Costs of Mental Retardation, Cerebral Palsy, Hearing Loss, and Vision Impairment 2003, Elsevier Science Ltd, London, England.
7. Stratton K.R., Durch J.S., Lawrence R.S.e. Vaccines for the 21st Century: a Tool for Decision Making 2001, National Academy Press, Washington DC.
8. Yoshinaga-Itano C., Coulter D., Thomson V. J. Perinatol. 2000, 20:S132-S137.
9. Yoshinaga-Itano C., Coulter D., Thomson V. Semin. Neonatol. 2001, 6:521-529.
10. Kimberlin D.W., Jester P.M., Sánchez P.J., Ahmed A., Arav-Boger R., Michaels M.G., et al. New Engl. J. Med. 2015, 372:933-943.
11. Menlove Ronda Rudd Cytomegalovirus Public Health Initiative 2013, Utah House of Representatives, Salt Lake City. UHo (Ed.).
12. E.J. Williams, J. Gray, S. Luck, C. Atkinson, N.D. Embleton, S. Kadambari, et al. First Estimates of the Potential Cost of Targeted Screening for Congenital CMV, Arch. Dis. Child. Fetal. Neonatal. Ed. published online doi: 10.1136/archdischild-2014-306756.
13. Utah State Legislature Fiscal Note HB0081 S02 Cytomegalovirus Public Health Initiative 2013, Utah State Legislature, Salt Lake City.
14. U.S. Census Bureau. Annual Social and Economic Supplement Current Population Survey, 2013.
15. Bergevin A. Personal Communication with Kobi Young at the Utah Department of Health 2014, Utah Department of Health, Salt Lake City.